Literature DB >> 23494655

Is concomitant quadruple therapy for Helicobacter pylori eradication really needed for Japanese patients?

Vincenzo De Francesco1, Angelo Zullo, Cesare Hassan.   

Abstract

The study found that the 7 d of concomitant therapy (lansoprazole, amoxicillin, clarithromycin and metronidazole) achieved significantly higher eradication rates compared to 7 d of triple therapy (lansoprazole, amoxicillin, clarithromycin), the intention to treat (ITT) cure rates being 94.9% and 68.3%, respectively. According to our opinion, this study is clinically relevant for Japanese physicians for at least 2 reasons: (1) the standard triple therapy (clarithromycin plus amoxicillin) achieved disappointing cure rates in Japan - in agreement with what was observed in several countries; and (2) the concomitant quadruple therapy is an effective therapeutic alternative.

Entities:  

Keywords:  Helicobacter pylori; Japanese patients; Triple therapy

Year:  2012        PMID: 23494655      PMCID: PMC3596515          DOI: 10.4292/wjgpt.v3.i6.103

Source DB:  PubMed          Journal:  World J Gastrointest Pharmacol Ther        ISSN: 2150-5349


  5 in total

1.  Non-bismuth quadruple therapy for first-line Helicobacter pylori eradication: A randomized study in Japan.

Authors:  Ayako Yanai; Kei Sakamoto; Masao Akanuma; Keiji Ogura; Shin Maeda
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-02-06

2.  Letter: the ethics of using inferior regimens in H. pylori randomised trials.

Authors:  D Y Graham; L A Fischbach
Journal:  Aliment Pharmacol Ther       Date:  2012-04       Impact factor: 8.171

Review 3.  Helicobacter pylori treatment in the era of increasing antibiotic resistance.

Authors:  David Y Graham; Lori Fischbach
Journal:  Gut       Date:  2010-06-04       Impact factor: 23.059

Review 4.  Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough.

Authors:  J P Gisbert; X Calvet
Journal:  Aliment Pharmacol Ther       Date:  2011-10-21       Impact factor: 8.171

5.  Helicobacter pylori eradication therapy research: Ethical issues and description of results.

Authors:  David Y Graham
Journal:  Clin Gastroenterol Hepatol       Date:  2010-07-23       Impact factor: 11.382

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.